Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies: The OPUS Anesthesia Pilot Trial
Launched by CHU DE QUEBEC-UNIVERSITE LAVAL · Mar 13, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The OPUS Anesthesia Pilot Trial is a study aimed at improving recovery after major surgery by testing two medications, dexmedetomidine and lidocaine, given during anesthesia. Many patients struggle to recover fully after surgery, which can affect their ability to return to daily activities. By using these medications, researchers hope to see if they can help patients feel better and recover faster after their procedures. This trial will help determine if it is feasible to conduct a larger study to evaluate their effects more thoroughly.
To participate in this trial, you need to be an adult aged 18 or older who is scheduled for a major surgery that requires general anesthesia and will involve at least one night in the hospital. However, there are some exclusions, such as having allergies to the medications being tested or certain health conditions that might make participation unsafe. If you join the study, you can expect to undergo the usual pre-surgery assessments and will be monitored closely to see how well you recover. This trial is still in the planning stages and hasn't started recruiting participants yet, but it aims to gather important information that could improve post-surgery care for many patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults \>/= 18 years.
- • 2. Having elective major non-cardiac surgery (i.e., planned duration \>/= 1.5 hours and anticipated \>/= 1 night hospital stay).
- • 3. Requiring general anesthesia.
- • 4. Able to complete baseline quality of recovery assessment.
- Exclusion Criteria:
- • 1. Individuals with known contraindications to dexmedetomidine or lidocaine (e.g., allergy to alpha-2 agonists or local anesthetics, severe renal or hepatic failure, bradycardia or hypotension), as per routine assessment.
- • 2. Regular use of alpha-2 agonists or local anesthetics prior to hospitalization.
- • 3. Pregnant women.
- • 4. Planned use of regional analgesia (i.e., epidural, peripheral nerve block, trunk nerve block) in conjunction with general anesthesia. Local anesthetics such as lidocaine are administered as part of regional analgesia technique. Combination with intravenous lidocaine is contraindicated to avoid exceeding therapeutic concentration.
- • 5. Planned postoperative intubation after PACU discharge.
- • 6. No fixed address.
About Chu De Quebec Universite Laval
CHU de Québec-Université Laval is a leading academic health center in Canada, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, it leverages its extensive network of healthcare professionals, researchers, and state-of-the-art facilities to conduct innovative clinical studies across various therapeutic areas. With a strong emphasis on collaboration and ethical standards, CHU de Québec-Université Laval aims to translate scientific discoveries into effective treatments, enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Québec, Quebec, Canada
Patients applied
Trial Officials
Michael Verret, MD PhD FRCPC
Principal Investigator
CHU de Quebec-Université Laval Research Center
Dean A. Fergusson, PhD
Principal Investigator
Ottawa Hospital Research Institute
Manoj M. Lalu, MD PhD FRCPC
Principal Investigator
Ottawa Hospital Research Institute
Alexis Turgeon, MD MSc FRCPC
Principal Investigator
CHU de Quebec-Université Laval Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported